Modern data on localized scleroderma and methods of its therapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Chronic localized scleroderma is a rare disease of the skin and subcutaneous tissue with an unknown etiology and pathogenesis, characterized by a variety of clinical variants. Pathological changes occur in the form of three consecutive stages of erythema or edema, induration and the formation of sclerosis and/or atrophy; however, such staging is not observed in all cases. Localized scleroderma covers a wide range of clinical variants, from solitary skin lesions with minimal discomfort to severe subtypes such as generalized or linear scleroderma. Research on development of a modern classification, clarification of the pathogenesis of the disease and effective methods of therapy is ongoing. Topical glucocorticosteroids are the first-line treatment for localized scleroderma. Ultraviolet A1 (UVA1) phototherapy is used to treat patients with advanced lesions.

全文:

受限制的访问

作者简介

Nina Filimonkova

Ural Research Institute of Dermatovenereology and Immunopathology

Email: nnfil2008@mail.ru
Dr. Sci. (Med.), Professor, Leading Researcher at the Scientific Clinical Department Yekaterinburg, Russia

A. Temirbulatova

Doctor Arbitaylo

Tyumen, Russia

I. Kuznetsov

Academician E.A. Vagner Perm State Medical University

Perm, Russia

参考

  1. Peterson L.S., Nelson A.M., Su W.P. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70:1068-76. doi: 10.4065/70.11.1068.
  2. Kunzler E., Florez-Pollack S., Teske N., et al. Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort. J Am Acad Dermatol. 2019;80:1664-70. Doi: 10.1016/j. jaad.2019.01.050.
  3. Teske N., Welser J., Jacobe H. Skin mapping for the classification of generalized morphea. J Am Acad Dermatol. 2018;78:351-57. Doi: 10.1016/j. jaad.2016.08.052.
  4. Mertens J.S., Seyger M.M.B., Thurlings R.M, Radstake T.R.D.J., de Jong EMGJ. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol. 2017;18(4):491-512. Doi: 10.1007/ s40257-017-0269-x.
  5. Zulian F., Vallongo C, Woo P., et al., Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-81. doi: 10.1002/art.21264.
  6. Laxer R.M., Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606-13. doi: 10.1097/01.bor.0000245727.40630.c3
  7. Ihn H., Sato S., Fujimoto M., et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287(2):193-97. doi: 10.1007/BF01262331.
  8. Careta M.F., Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90:62-73. Doi: 10.1590/ abd1806-4841.20152890.
  9. Wadud M.A., Bose B.K., Al Nasir T. Familial localised scleroderma from Bangladesh: two case reports. Bangladesh Med Res Counc Bull. 1989;15:15-9.
  10. O'Brien J.C., Rainwater Y.B., Malviya N., et al. Transcriptional and Cytokine Profiles identify CXCL9 as a Biomarker of Disease Activity in Morphea. J Investig Dermatol. 2017;137:1663-doi: 10.1016/j.jid.2017.04.008.
  11. Grabell D., Hsieh C., Andrew R., et al. The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IV. J Am Acad Dermatol. 2014;71:493-98. Doi: 10.1016/j. jaad.2014.04.009.
  12. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64:217-228; quiz 229-30. doi: 10.1016/j.jaad.2010.05.045.
  13. Prasad S, Zhu JL, Schollaert-Fitch K, et al. Characterizing morphea subsets using a multicenter, prospective, cross-sectional analysis of morphea in adults and children. J Investig Dermatol. 2020;140:S73.
  14. Badea I., Taylor M., Rosenberg A., et al. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford). 2009;48:213-21. Doi: 10.1093/ rheumatology/ken405.
  15. Kroft E.B., Groeneveld T.J., Seyger M.M., de Jong E.M. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181-87. doi: 10.2165/00128071-200910030 00004.
  16. Kreuter A., Hyun J., Stucker M., et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440-47. Doi: 10.1016/j. jaad.2005.11.1063.
  17. Joly P, Bamberger N., Crickx B., Belaich S. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994; 130(5):663-64.
  18. Zulian F., Martini G., Vallongo C., et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998-2006. doi: 10.1002/art.30264.
  19. Старовойтова М.Н., Десинова О.В. Опыт применения актовегина при очаговой склеродермии. Современная ревматология. 2013;3:42-

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##